New American Kidney Fund Education Campaign Highlights Connection Between Kidney Disease and Gout
21 août 2018 10h05 HE
|
American Kidney Fund
ROCKVILLE, Md., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aiming to demystify gout, an extremely painful form of inflammatory arthritis, the American Kidney Fund (AKF) today unveiled a new health education...
National Gout Awareness Day: American Kidney Fund Highlights Connection Between Gout and Kidney Disease
22 mai 2018 11h15 HE
|
American Kidney Fund
ROCKVILLE, Md., May 22, 2018 (GLOBE NEWSWIRE) -- Tuesday, May 22, is National Gout Awareness Day and the American Kidney Fund (AKF) is joining a nationwide effort to educate people about the...
Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
22 mai 2018 09h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today marked Gout Awareness Day with the launch of Gout Revealed, which was created to spotlight real-life stories...
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
07 nov. 2017 07h30 HE
|
Selecta Biosciences, Inc.
Patient Data From Ongoing Phase 2 Trial to be Presented Today at the American College of Rheumatology (ACR) 2017 Annual MeetingPreparations for Phase 3 Program UnderwayReceived $7.5 Million From Spark...
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
06 nov. 2017 12h00 HE
|
Horizon Pharma plc
-- Initial data from investigator-initiated TRIPLE study shows infusion reactions occurred in less than 1 percent of infusions -- -- Analyses further support the efficacy and safety of KRYSTEXXA -- ...
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
03 nov. 2017 11h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual Meeting
23 oct. 2017 08h00 HE
|
Horizon Pharma plc
-- Initial data from investigator-initiated TRIPLE study to be presented on Nov. 6 -- -- Horizon Pharma plc to host an investor call on Nov. 9 following the ACR/AHRP Annual Meeting -- DUBLIN,...
Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout
15 juin 2017 07h30 HE
|
Selecta Biosciences
WATERTOWN, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout
14 juin 2017 09h05 HE
|
Horizon Pharma plc
DUBLIN, Ireland, June 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993
14 juin 2017 09h00 HE
|
Horizon Pharma plc
MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to be presented tomorrow at the Annual European Congress of Rheumatology (EULAR) 2017 show a 410 percent increase in...